Positive Urine Cytology Reveals Melanoma - Scorecard - MDSpire

Positive Urine Cytology Reveals Melanoma

Rare case links prior melanoma in situ to ureter and porta hepatis metastases

  • By

  • Jess Allerton

  • February 16, 2026

  • 3 min

Share

Clinical Scorecard: Positive Urine Cytology Reveals Melanoma

At a Glance

CategoryDetail
ConditionMetastatic Melanoma
Key MechanismsMetastasis from previously excised melanoma in situ, identified through urine cytology and histopathology.
Target PopulationPatients with a history of melanoma in situ presenting with atypical genitourinary symptoms.
Care SettingOncology and Urology clinics.

Key Highlights

  • Metastatic melanoma can occur years after excision of melanoma in situ.
  • Urine cytology may reveal atypical cells indicative of metastatic melanoma.
  • Differential diagnosis should include metastatic melanoma in atypical ureteral tumors.

Guideline-Based Recommendations

Diagnosis

  • Utilize comprehensive morphologic assessment and immunohistochemical panels for atypical ureteral tumors.

Management

  • Refer for systemic immunotherapy, such as pembrolizumab, upon diagnosis of metastatic melanoma.

Monitoring & Follow-up

  • Regular imaging and clinical evaluations to detect potential metastasis.

Risks

  • Late metastasis may occur in cases of melanoma in situ due to occult microinvasion.

Patient & Prescribing Data

Older adults with a history of melanoma in situ.

Systemic immunotherapy is a key treatment approach for disseminated metastatic melanoma.

Clinical Best Practices

  • Integrate clinical history, imaging, morphology, and immunophenotyping for accurate diagnosis.
  • Consider metastatic melanoma in differential diagnoses for unusual genitourinary lesions.

Related Resources & Content

Original Source(s)

Positive Urine Cytology Reveals Melanoma

  • by Jess Allerton

  • February 16, 2026

Related Content

AI Outperforms MDs on Reasoning Tasks

Across six experiments—including a blinded, real-world ER evaluation—an OpenAI large language model outperformed physician baselines on multiple clinical reasoning tasks, though not on key safety endpoints such as cannot-miss diagnoses

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches

IOPTH Widely Used, Variation Persists

Most surgeons reported using intraoperative parathyroid hormone monitoring, but approaches to imaging and intraoperative criteria varied, particularly in secondary and tertiary disease